LCG
HRMY icon

Lisanti Capital Growth’s Harmony Biosciences HRMY Stock Holding History

Lisanti Capital Growth’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-54,800
Closed -$1.93M – 140
2023
Q2 		$1.93M Buy
+54,800
New +$1.89M 0.27% 116
2023
Q1 		– Sell
-193,830
Closed -$10.7M – 130
2022
Q4 		$10.7M Sell
193,830
-54,240
-22% -$2.98M 1.46% 18
2022
Q3 		$11M Sell
248,070
-55,795
-18% -$2.72M 1.47% 20
2022
Q2 		$14.8M Buy
+303,865
New +$13.7M 2.01% 11

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Lisanti Capital Growth's HRMY Position: Q3 2023 in Review

Lisanti Capital Growth sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 54,800 shares — an estimated $1.93M sold.

Lisanti Capital Growth first reported a position in HRMY in Q2 2022 and held it in 4 quarters. The position peaked at $14.8M in Q2 2022. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • Lisanti Capital Growth reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • Lisanti Capital Growth sold 54,800 Harmony Biosciences shares in Q3 2023, an estimated $1.93M.
  • Lisanti Capital Growth first reported a position in Harmony Biosciences in Q2 2022 and held it in 4 quarters.
  • Lisanti Capital Growth's Harmony Biosciences position peaked at $14.8M in Q2 2022.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Lisanti Capital Growth's 13F filing for Q3 2023, filed 3 Nov 2023.